18-FDG-PET

DEVICE3 trials

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France, National Cancer Institute (NCI), Central Hospital, Nancy, France

Conditions

Amyotrophic Lateral SclerosisB-Cell LymphomaChronic Lymphocytic LymphomaFollicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaSpastic Paraplegia

Phase 1

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

CompletedNCT04599634

National Cancer Institute (NCI)B-Cell Lymphoma, Chronic Lymphocytic Lymphoma, Follicular Lymphoma +2

Start: 2021-12-16End: 2024-06-20Updated: 2025-02-04

Unknown Phase

Brown Adipose Tissue in ALS

CompletedNCT03150290

Institut National de la Santé Et de la Recherche Médicale, FranceAmyotrophic Lateral Sclerosis

Start: 2017-10-26End: 2019-04-01Updated: 2021-08-26

Cognitive Disorders in Hereditary Spastic Paraplegia Type 4

RecruitingNCT06260982

Central Hospital, Nancy, FranceSpastic Paraplegia

Start: 2022-01-01End: 2025-01-02Target: 30Updated: 2024-02-15

Related Papers

Phase I Study of Response-Adapted Treatment with Venetoclax, Obinutuzumab, and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-Cell Malignancies

Blood2023-11-023 citations